Trials / Recruiting
RecruitingNCT06065930
Adaptive Mechanisms In GRown up ObeSity Study (AMIGROS)
Mechanistic Studies in Human Subcutaneous Adipose Tissue
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- Vastra Gotaland Region · Other Government
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The investigator recently showed that the glycan-binding adipokine galectin-1 increased during overfeeding and that galectin-1 independently could predict type 2 diabetes. Further, the molecules that induce insulin release in the fasting state when blood glucose is normal remain elusive. It is possible that galectin-1 is involved in adaptive mechanisms in adipose tissue in obese subjects.
Detailed description
The investigator will define adaptive mechanisms in adipose tissue associated with galectin-1 in obese insulin-sensitive (Ob-IS) subjects compared with obese insulin-resistant (Ob-IR) subjects and lean healthy controls. Further, the investigator will study molecules secreted from adipose tissue that might trigger insulin secretion when blood glucose is normal. The investigator hypothesizes that Ob-IS subjects keep fatty acid levels normal through an adaptive response in adipose tissue that involves up-regulation of galectin-1 for dampening of immune cell activity and stimulation of lipolysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Subcutaneous microdialysis | Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1. Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1. Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1. |
Timeline
- Start date
- 2023-05-05
- Primary completion
- 2025-12-31
- Completion
- 2028-12-31
- First posted
- 2023-10-04
- Last updated
- 2023-10-04
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT06065930. Inclusion in this directory is not an endorsement.